EyePoint Pharmaceuticals' EYP-1901: Promising Novel Drug Delivery System
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
EyePoint Pharmaceuticals' EYP-1901: Promising Novel Drug Delivery System
-
Narrado por:
-
De:
In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.
Brought to you by Alcon
· Welcome to another exciting episode of Eye Care insider :13
· Intro Nancy Lurker :22
· Lurker's background :58
· EyePoint Pharmaceuticals: the origin and transition 2:29
· Yutiq and long-acting drug delivery systems 6:07
· Additional indications for Yutiq 8:30
· What is the key factor in delivering this longer durability? 16:13
· Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47
· Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19
· Investor information and neural protection data 29:01
· What is the most important issue that the field of ophthalmology is currently facing? 30:38
· Thanks for listening 32:37
We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.
Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.
Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.